2026年1月2日，北京大学生命科学学院伊成器教授课题组在Nature Biotechnology在线发表研究论文。该研究建立了由单链脱氨酶辅助的可调节RNA信息操纵平台AIM（adjustable RNA information manipulation）。该平台突破了目前RNA碱基编辑工具“单点编辑”的限制，实现了在RNA靶向区域内对不同数量、多种类型碱基的可 ...

ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...

In a paper published on aBIOTECH, the authors investigated the off-target effects of ADAR-mediated RNA editing in rice ...

Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity ...

A research team led by Rice's Yang Gao has uncovered new insights into the molecular mechanisms of ADAR1. ADAR1 converts adenosine to inosine in double-stranded RNA, a process essential for preventing ...

Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.

After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop ...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today ...

Parkinson's disease (PD) is a neurodegenerative disorder in which the α-synuclein protein abnormally aggregates within brain cells, causing neuronal damage. Through international collaboration, ...

Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...